BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,249,322 | +21.7% | 363,968 | 0.0% | 0.00% | +100.0% |
Q1 2024 | $1,848,957 | -17.3% | 363,968 | -2.5% | 0.00% | -50.0% |
Q4 2023 | $2,237,073 | -23.9% | 373,468 | -10.1% | 0.00% | 0.0% |
Q3 2023 | $2,940,805 | +1.8% | 415,368 | +1.2% | 0.00% | 0.0% |
Q2 2023 | $2,888,991 | -13.9% | 410,368 | +2.0% | 0.00% | 0.0% |
Q1 2023 | $3,355,749 | -34.9% | 402,368 | -10.4% | 0.00% | -50.0% |
Q4 2022 | $5,154,153 | -7.1% | 448,968 | +2.0% | 0.00% | 0.0% |
Q3 2022 | $5,546,000 | +20.5% | 440,168 | +1.2% | 0.00% | +33.3% |
Q2 2022 | $4,602,000 | -33.5% | 434,968 | +2.2% | 0.00% | -25.0% |
Q1 2022 | $6,918,000 | +27.2% | 425,468 | +8.4% | 0.00% | +33.3% |
Q4 2021 | $5,437,000 | -3.6% | 392,568 | 0.0% | 0.00% | -25.0% |
Q3 2021 | $5,641,000 | -8.5% | 392,568 | +0.7% | 0.00% | 0.0% |
Q2 2021 | $6,164,000 | +50.2% | 389,868 | -3.4% | 0.00% | +33.3% |
Q1 2021 | $4,103,000 | +38.0% | 403,468 | +1.1% | 0.00% | +50.0% |
Q4 2020 | $2,974,000 | +120.8% | 399,168 | +1.8% | 0.00% | +100.0% |
Q3 2020 | $1,347,000 | -26.7% | 392,268 | +1.7% | 0.00% | -50.0% |
Q2 2020 | $1,838,000 | +207.4% | 385,668 | +29.1% | 0.00% | +100.0% |
Q1 2020 | $598,000 | -39.0% | 298,800 | +5.2% | 0.00% | 0.0% |
Q4 2019 | $980,000 | +144.4% | 284,000 | +103.0% | 0.00% | – |
Q3 2019 | $401,000 | -24.3% | 139,900 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $530,000 | -53.5% | 139,900 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $1,139,000 | +4.2% | 139,900 | +3.3% | 0.00% | 0.0% |
Q4 2018 | $1,093,000 | +19.3% | 135,400 | +12.8% | 0.00% | 0.0% |
Q3 2018 | $916,000 | +33.1% | 120,000 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $688,000 | -15.8% | 120,000 | -29.9% | 0.00% | 0.0% |
Q1 2018 | $817,000 | -2.9% | 171,300 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $841,000 | -6.3% | 171,300 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $898,000 | +41.2% | 171,300 | +49.9% | 0.00% | 0.0% |
Q2 2017 | $636,000 | -33.8% | 114,300 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $960,000 | +57.4% | 114,300 | +18.7% | 0.00% | 0.0% |
Q4 2016 | $610,000 | +43.5% | 96,300 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $425,000 | +55.7% | 96,300 | 0.0% | 0.00% | – |
Q2 2016 | $273,000 | +3.8% | 96,300 | 0.0% | 0.00% | – |
Q1 2016 | $263,000 | -67.5% | 96,300 | +22.8% | 0.00% | -100.0% |
Q4 2015 | $809,000 | -9.5% | 78,400 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $894,000 | -12.2% | 78,400 | +15.0% | 0.00% | -33.3% |
Q2 2015 | $1,018,000 | +69.9% | 68,200 | +2.9% | 0.00% | +50.0% |
Q1 2015 | $599,000 | -25.7% | 66,300 | 0.0% | 0.00% | -33.3% |
Q4 2014 | $806,000 | +29.0% | 66,300 | +3.8% | 0.00% | +50.0% |
Q3 2014 | $625,000 | -34.5% | 63,900 | -14.6% | 0.00% | -50.0% |
Q2 2014 | $954,000 | +63.4% | 74,800 | +35.5% | 0.00% | +100.0% |
Q1 2014 | $584,000 | +75.4% | 55,200 | +26.0% | 0.00% | +100.0% |
Q4 2013 | $333,000 | – | 43,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |